Chemical Structure : Lysosome inhibitor LLAD
CAS No.:
2980757-71-7
Lysosome inhibitor LLAD
Catalog No.: PC-25859Not For Human Use, Lab Use Only.
LLAD is a long-term lysosome-targeting anticancer drug, inhibits SLC38A9 in lysosomes and alkalinizes lysosomes, induces apoptosis through long-term lysosomal damage in vivo and in vitro.
Bulk size, bulk discount!
Welcome credit card payment!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Purity & Documentation Purity:
>98% (HPLC)
Biological Activity
LLAD is a long-term lysosome-targeting anticancer drug, inhibits SLC38A9 in lysosomes and alkalinizes lysosomes, induces apoptosis through long-term lysosomal damage in vivo and in vitro.
LLAD exhibited a potent binding ability with SLC38A9 with SPR KD of 1.29 uM.
LLAD shows anti-proliferation activity with IC50 of 26.66 uM in A549 cells and 2.478 uM in HL-60 cells.
directly inhibit the activity of SLC38A9, inhibits mTOR signaling pathway and phosphorylation of mTOR and the substrates S6 kinase (S6K).
LLAD induces lysosomal damage (lysosomal stress response, LSR) by long-term retention.
LLAD (2.5 mg/kg) exhibited excellent long-term anticancer effect in HeLa xenograft mouse model.
Physicochemical Properties
|
M.Wt
|
401.47
|
|
Formula
|
C22H23N7O
|
|
Appearance
|
Solid
|
|
CAS No.
|
|
|
Storage
|
- Solide Powder
-
-20°C 12 Months; 4°C 6 Months
|
- In Solvent
-
-80°C 6 Months; -20°C 6 Months
|
|
Shipping
|
|
|
Solubility
|
10 mM in DMSO
|
|
Chemical Name/SMILES
|
N-(3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-indazol-4-yl)acrylamide
|
References
1. Zhao S, et al. Acta Pharm Sin B. 2025 Nov;15(11):5867-5879.
Contact Us
sales@probechem.com
